Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 19/20 | 0.73 |
| ▸ | DDB1 | Q16531 | 18/20 | 0.73 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.39 |
| ▸ | IKZF2 | Q9UKS7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26328140 | 0.87 | CRBN (0.56) | CRBNDDB1IKZF1IKZF2 | |
| SCHEMBL21965363 | 0.84 | CRBN (1.00) | CRBNDDB1 | |
| SCHEMBL21965731 | 0.84 | CRBN (0.72) | CRBNDDB1 | |
| SCHEMBL21965836 | 0.82 | DDB1 (0.61) | CRBNDDB1 | |
| SCHEMBL25566985 | 0.82 | DDB1 (0.69) | CRBNDDB1IKZF1IKZF2 | |
| SCHEMBL27362723 | 0.82 | DDB1 (0.69) | CRBNDDB1IKZF1IKZF2 | |
| SCHEMBL21965369 | 0.82 | CRBN (0.69) | CRBNDDB1 | |
| SCHEMBL21965347 | 0.81 | DDB1 (0.72) | CRBNDDB1 | |
| SCHEMBL23540323 | 0.79 | DDB1 (0.64) | CRBNDDB1 | |
| SCHEMBL20812435 | 0.79 | CRBN (0.47) | CRBNDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | C4 THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | C4 THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20200140456-A1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | CRBN, CBL, STUB1 | CRBN 1/4885DDB1 319/4885IKZF1 4/4885 |
| US-20200140456-A1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | CRBN, CBL, STUB1 | CRBN 1/4885DDB1 319/4885IKZF1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.